[0001] The present invention relates to cyclodextrin-based polymers for therapeutics delivery. Specifically, the present invention relates to conjugate of cyclodextrin with polyvinyl-pyrrolidine, for therapeutic agent delivery for treating dental carries and biofilm formation. The present invention further relates to a method of making the polymer conjugate of cyclodextrin with polyvinyl-pyrrolidine.

BACKGROUND OF THE INVENTION
[0002] Background description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0003] Dental cavity (also known as caries or dental caries)is the most common non-communicable condition (NCD) and a major public health problem worldwide. It is also the most common condition for permanent teeth (2-3 billion people) and the 12thfor leaking teeth (560 million children) in the 2015 Global Burden of Disease Study. The avoidance of dietary free sugars is known to prevent caries. Furthermore, dental caries is largely preventable by the simple, cost-effective intervention of the population and the patient, while care in low and middle - income countries is expensive and often unavailable. Caries-affected teeth are often lost (removed) after experiencing pain or discomfort. Extreme dental caries, including diet and sleeping problems, can decrease the quality of life and may lead to pain and persistent systemic infection or negative growth habits in advanced stages (abscesses). Dental damage is a common cause of school or work absence. Severe dental caries affects overall health and often cause tooth extraction pain and infection. Dental caries in industrialized countries are an expensive treatment disease, which consumes 5–10 percent of health budgets and is one of the main reasons for child hospitalization in some high - income countries. Dental cavities may be found in two specified areas of the teeth: occlusal cavity in the top-most portion of the tooth where food particles come in direct contact with the teeth repeatedly and interproximal cavities that form dental caries between the teeth.
[0004] Cyclodextrins (CD) are a family of cyclic oligosaccharides, consisting of a macrocyclic ring of glucose subunits joined by a-1,4glycosidic bonds. Cyclodextrin belongs to the most important and promising macrocyclic hosts, since they are inexpensive, water-soluble natural products, non-toxic, readily functionalized and commercially available. Cyclodextrins easily form complexes with hydrophobic compounds as they possess a hydrophobic interior and hydrophilic exterior are all generally recognized as safe by the USFDA. Cyclodextrins are well-known for their ability to act as a ring-shaped host for hydrophobic molecules and thus act as drug carriers.
[0005] The uses of cyclodextrin containing polymers for the delivery of molecules for therapeutic needs are of utmost interest. Studies on humans as well as animals show that CDs can be used from almost any type of drug formula to improve drug delivery. At present there are about 30 drug/CD compounds in the worldwide pharmaceutical products. Such therapeutic agents, which have a problem because of their properties, are often water - soluble and have low bioactive shape in contrast with the inactive form, or the high systemic nature of such additives.
[0006] Inspite of several drug delivery systems comprising cyclodextrin being available in the market, wherein supramolecular complexing is utilizing, there is no drug delivery system available which can penetrate biofilms in dental carries and solubilize bacterial based dental carries. Consequently, there is still an unmet need for new polymer conjugates as drug delivery systems for targeted delivery that possess required pharmacological properties and provide continuous release formulations that resolve, stabilize or avoids complications related to high systematic amounts of the therapeutic agent. The present invention provides novel delivery systems comprising cyclodextrin based polymer conjugates for therapeutic delivery, which overcome the deficiencies associated with the art and are useful for the treatment of dental carries and prevention of bacterial formation due to biofilm production.
OBJECTS OF THE INVENTION
[0007] An object of the present invention is to provide cyclodextrin based polymer conjugates for therapeutic delivery, which can overcome the deficiencies associated with the art and are useful for the treatment of dental carries and prevention of bacterial formation due to biofilm production.
[0008] Another object of the present invention is to providecyclodextrinbased polymer conjugates which can penetrate biofilms in dental carries and solubilize bacterial based dental carries.
[0009] Yet another object of the present invention is to provide cyclodextrin based polymer conjugates for targeted delivery that possess required pharmacological properties and provide continuous release formulations.
[0010] Still another object of the present invention is to provide a method for preparing the cyclodextrin based polymer conjugates.
[0011] Another object of the present invention is to provide cyclodextrin based polymer conjugates that can be easily manufactured and reduce the overall production costs.
[0012] The other objects and preferred embodiments and advantages of the present invention will become more apparent from the following description of the present invention when read in conjunction with the accompanying examples and figures, which are not intended to limit scope of the present invention in any manner.

SUMMARY OF THE INVENTION
[0013] This summary is provided to introduce a selection of concepts in a simplified form that are further described below in Detailed Description section. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
[0014] The present invention relates to cyclodextrin-based inclusion polymers for therapeutics delivery. Specifically, the present invention relates to conjugate of cyclodextrin with polyvinyl-pyrrolidone (CD-PVP), for therapeutic agent delivery for treating dental carries and biofilm formation.
[0015] The term “inclusion polymers” and “polymer conjugates” represents the same concept and can be used interchangeably.
[0016] In one aspect, the present invention relates to polymer conjugate of cyclodextrin, for therapeutic agent delivery for treating dental carries and biofilm formation, wherein the polymer conjugate comprises cyclodextrin, polymer, therapeutic drug, silicon nanoparticles and a cross-linker.
[0017] In one aspect, the present invention relates to polymer conjugate of cyclodextrin, wherein the polymer conjugate optionally comprises a target ligand.
[0018] In another aspect, the present invention relates to polymer conjugate of cyclodextrin, wherein cyclodextrin is preferably ß-cyclodextrin.
[0019] In another aspect, the present invention relates to polymer conjugate of cyclodextrin, wherein the polymer is a water soluble polymer, polyvinyl-pyrrolidone (PVP).
[0020] In another aspect, the present invention relates to polymer conjugate of cyclodextrin, wherein therapeutic agent may be selected from but not limited to Doxycycline, ciprofloxacin, bupivacaine 2-hydroxypropyl-ß-cyclodextrin and the like.
[0021] In another aspect, the present invention relates to polymer conjugate of cyclodextrin, wherein therapeutic agentcan be added to the CD-PVP complex through a linker.
[0022] In another aspect, the present invention relates to polymer conjugate of cyclodextrin, wherein the linker for adding the therapeutic agent to CD-PVP complex is selected from but not limited to PEG polymer, Folic acid, mono- and oligosaccharides, hyaluronic acid (HA) or an antibody.
[0023] In another aspect, the present invention relates to polymer conjugate of cyclodextrin, wherein the target lig and is selected from but not limited to Doxycycline, ciprofloxacin, bupivacaine 2-hydroxypropyl-ß-cyclodextrin and the like.
[0024] In another aspect, the present invention relates to polymer conjugate of cyclodextrin, wherein the target lig and may be mounted on the monomer via an optional linker or grafted on to the polymer via an optional linker, or the combination can be bound as an inclusion complex or host-guest.
[0025] In another aspect, the present invention relates to a polymer conjugate of cyclodextrin, wherein the polymer conjugate is water-soluble and linear.
[0026] In another aspect, the present invention relates to a polymer conjugate of cyclodextrin, wherein the polymer conjugate displays high solubility in water, low toxicity and low immune response.
[0027] In another aspect, the present invention relates to a polymer conjugate of cyclodextrin, wherein the polymer conjugate is capable of targeted delivery of therapeutic agents at a controlled rate in penetrating biofilms especially for dental carries.
[0028] In another aspect, the present invention relates to a polymer conjugate of cyclodextrin, wherein the polymer conjugate does not alter the therapeutic efficacy of the therapeutic agent used.
[0029] In another aspect, the present invention relates to polymer conjugate of cyclodextrin, wherein CD-PVP is encapsulated with lipophilic allyl-benzyl-capped silicon nanoparticles to form monodispersable particles. Liposomal and cellular absorption of mono dispersed particles have normally been found to be low cytotoxic when used for therapeutic agents.
[0030] In another aspect, the present invention relates to polymer conjugate of cyclodextrin, wherein CD-PVP is bound to lipophilic allyl-benzyl-capped silicon nanoparticles with a homodifunctionalized cross-linker, glutaraldehyde for easy enzymatic digestion and for releasing drug targets.
[0031] In another aspect, the present invention relates to polymer conjugate of cyclodextrin, wherein the resulting complex can be combined neutrally to FMCG products used to treat or prevent dental carries. The FMCG product used to treat or prevent dental carries can be selected from Doxycycline, eugenol, ciprofloxacin, bupivacaine 2-hydroxypropyl-ß-cyclodextrinand the like.
[0032] In another aspect, the present invention relates to polymer conjugate of cyclodextrin, wherein the cyclodextrin moiety and PVP co-monomer are arranged with alternating water-soluble linear polymers of CD-PVP that are covalently bound to therapeutic agent.
[0033] In another aspect, the present invention relates toa method of making the polymer conjugate of cyclodextrin with polyvinyl-pyrrolidine.
[0034] In another aspect, the present invention relates to a method of making the polymer conjugate of cyclodextrin with polyvinyl-pyrrolidine comprising the steps of:
a) adding?- cyclodextrin to polyvinyl-pyrrolidine in the amount of 20%w/v;
b) Incubating the mixture of step a) at 90 degrees C for 1 hour, using a waterbath;
c) addition of sodium hydroxide after 5-10 min of incubation;
d) incubating the mixture of step c) at 90 degrees C for 6 hours; and
e) taking readings at 450 nm to characterize and confirm the product.
[0035] Other aspects of the invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learnt by the practice of the invention.

DETAILED DESCRIPTION
[0036] The following is a detailed description of embodiments of the disclosure. The embodiments are in such detail as to clearly communicate the disclosure. However, the amount of detail offered is not intended to limit the anticipated variations of embodiments; on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present disclosure as defined by the appended claims.
[0037] All publications herein are incorporated by reference to the same extent as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
[0038] Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0039] In some embodiments, the numbers expressing quantities of ingredients, properties such as concentration, reaction conditions, and so forth, used to describe and claim certain embodiments of the invention are to be understood as being modified in some instances by the term “about.”Accordingly, in some embodiments, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The numerical values presented in some embodiments of the invention may contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0040] As used in the description herein and throughout the claims that follow, the meaning of “a,” “an,” and “the” includes plural reference unless the context clearly dictates otherwise. Also, as used in the description herein, the meaning of “in” includes “in” and “on” unless the context clearly dictates otherwise.
[0041] Unless the context requires otherwise, throughout the specification which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense that is as “including, but not limited to.”
[0042] The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein.All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. “such as”) provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0043] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
[0044] The description that follows, and the embodiments described therein, is provided by way of illustration of an example, or examples, of particular embodiments of the principles and aspects of the present disclosure. These examples are provided for the purposes of explanation, and not of limitation, of those principles and of the disclosure.
[0045] It should also be appreciated that the present disclosure can be implemented in numerous ways, including as a system, a method or a device. In this specification, these implementations, or any other form that the invention may take, may be referred to as processes. In general, the order of the steps of the disclosed processes may be altered within the scope of the invention.
[0046] The headings and abstract of the invention provided herein are for convenience only and do not interpret the scope or meaning of the embodiments.
[0047] The following discussion provides many example embodiments of the inventive subject matter. Although each embodiment represents a single combination of inventive elements, the inventive subject matter is considered to include all possible combinations of the disclosed elements. Thus if one embodiment comprises elements A, B, and C, and a second embodiment comprises elements B and D, then the inventive subject matter is also considered to include other remaining combinations of A, B, C, or D, even if not explicitly disclosed.
[0048] Various terms as used herein are shown below. To the extent a term used in a claim is not defined below, it should be given the broadest definition persons in the pertinent art have given that term as reflected in printed publications and issued patents at the time of filing.
[0049] The present invention relates to cyclodextrin-based inclusion polymers for therapeutics delivery. Specifically, the present invention relates to conjugate of cyclodextrin with polyvinyl-pyrrolidone (CD-PVP), for therapeutic agent delivery for treating dental carries and biofilm formation.
[0050] Currently, most studies on cyclodextrin conjugates focus on its ability to form supramolecular complexes, however none of the studies have conjugated and elongated the cyclodextrin molecule with polyvinyl-pyrrolidone (PVP) to make it more soluble for penetrating biofilms in dental carries. The drug delivery problem for breaking or solubilizing biofilms in dental carries has thus been solved by the novel polymer conjugate of the present invention comprising CD-PVP complex and therapeutic drug. The polymer conjugate of the present invention comprising cyclodextrin and polyvinyl-pyrrolidone is referred to as CD-PVP.
[0051] In one embodiment, the present invention relates to polymer conjugate of cyclodextrin, for therapeutic agent delivery for treating dental carries and biofilm formation, wherein the polymer conjugate comprises cyclodextrin, polymer, therapeutic drug, silicon nanoparticles and a cross-linker.
[0052] In another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein the polymer conjugate optionally comprises a target lig and.
[0053] In yet another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein cyclodextrin is preferably?-cyclodextrin.
[0054] In still another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein the polymer is a water soluble polymer, polyvinyl-pyrrolidone (PVP).
[0055] In another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein the polymer can be linear or wired and polycondensed with monomers that contain cyclodextrin, one or more that contain no monomers or cyclodextrin motives. It can be combined with other PVP comonomers by copolymerization.
[0056] In yet another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein therapeutic agent may be selected from but not limited to Doxycycline, ciprofloxacin, bupivacaine 2-hydroxypropyl-ß-cyclodextrinand the like.
[0057] In still another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein therapeutic agent can be added to the CD-PVP complex through a linker.
[0058] In another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein the linker for adding the therapeutic agent to CD-PVP complex is selected from but not limited to PEG polymer, Folic acid, mono- and oligosaccharides, hyaluronic acid (HA) or an antibody.
[0059] In yet another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein therapeutic agent can be added before the polymerization process depending on the desired drug / polymer proportion and properties.
[0060] In still another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein the target lig and is selected from but not limited to Doxycycline, ciprofloxacin, bupivacaine 2-hydroxypropyl-ß-cyclodextrinand the like.
[0061] In another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein the target lig and may be mounted on the monomer via an optional linker or grafted on to the polymer via an optional linker, or the combination can be bound as an inclusion complex or host-guest.
[0062] In another embodiment, the present invention relates to a polymer conjugate of cyclodextrin, wherein the polymer conjugate is water-soluble and linear.
[0063] In yet another embodiment, the present invention relates to a polymer conjugate of cyclodextrin, wherein the polymer conjugate displays high solubility in water, low toxicity and low immune response.
[0064] In still another embodiment, the present invention relates to a polymer conjugate of cyclodextrin, wherein the polymer conjugate is capable of targeted delivery of therapeutic agents at a controlled rate in penetrating biofilms especially for dental carries.
[0065] In another embodiment, the present invention relates toapolymer conjugate of cyclodextrin, wherein the polymer conjugate does not alter the therapeutic efficacy of the therapeutic agent used.
[0066] In order to decrease the cytotoxicity of cell surrounding the treatment area and better absorption of the drug, the CD-PVP is encapsulated with appropriate lipophilic nanoparticles.
[0067] In another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein CD-PVP is encapsulated with lipophilic allyl-benzyl-capped silicon nanoparticles to form mono dispersable particles. Liposomal and cellular absorption of monodispersed particles have normally been found to be low cytotoxic when used for therapeutic agents.
[0068] The biological activity of nanoparticles is influenced by unique scale, shape and surface chemistry. For lipophilic nanoparticles, commonly used in consumer goods, it is shown that the size and composition of particles affect skin permeability and that lipophilic particles less than 6 nm can be injected into lipid bilayers.
[0069] In another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein the nanoparticles of lipophilic allyl-benzyl-capped silicone in a single fraction have size in the range of 1 nm and 5 nm.
[0070] In yet another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein a particular size of the nanoparticles of lipophilic allyl-benzyl-capped silicone is separated using selective precipitation.
[0071] In still another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein CD-PVP is bound to lipophilic allyl-benzyl-capped silicon nanoparticles with a homodifunctionalized cross-linker, glutaraldehyde for easy enzymatic digestion and for releasing drug targets.
[0072] In another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein the resulting complex can be combined neutrally to FMCG products used to treat or prevent dental carries. The FMCG product used to treat or prevent dental carries can be selected from Doxycycline, eugenol, ciprofloxacin, bupivacaine 2-hydroxypropyl-ß-cyclodextrinand the like.
[0073] In another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein the cyclodextrin moiety and PVP co-monomer are arranged with alternating water-soluble linear polymers of CD-PVP that are covalently bound to therapeutic agent.
[0074] In yet another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein co-polymerizing of CD and PVP leads to conjugates having reactive site to covalently bind PVP and opening another site for binding therapeutic agent or for forming CD-PVP alternating cassette intercalating the therapeutic agent.
[0075] In still another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein water-soluble linear polymers containing cyclodextrin become a single unit having open reactive sites for linking therapeutic drug.
[0076] In another embodiment, the present invention relates to polymer conjugate of cyclodextrin, wherein functional group of lipophilic allyl-benzyl-capped silicon nanoparticles opens to accommodate drug targets at the site.
[0077] In another embodiment, the present invention relates to a method of making the polymer conjugate of cyclodextrin with polyvinyl-pyrrolidine.
[0078] In another embodiment, the present invention relates to a method of making the polymer conjugate of cyclodextrin with polyvinyl-pyrrolidine comprising the steps of :
a) adding?- cyclodextrin to polyvinyl-pyrrolidinein the amount of 20%w/v;
b) Incubating the mixture of step a) at 90 degrees C for 1 hour, using a waterbath;
c) addition of sodium hydroxide after 5-10 min of incubation;
d) incubating the mixture of step c) at 90 degrees C for 6 hours; and
e) taking readings at 450 nm to characterize and confirm the product.
[0079] While the foregoing describes various embodiments of the disclosure, other and further embodiments of the disclosure may be devised without departing from the basic scope thereof. The scope of the invention is determined by the claims that follow. The invention is not limited to the described embodiments, versions or examples, which are included to enable a person having ordinary skill in the art to make and use the invention when combined with information and knowledge available to the person having ordinary skill in the art.

Claims:1. A polymer conjugate of cyclodextrin (CD), for therapeutic agent delivery for treating dental carries and biofilm formation, wherein the polymer conjugate comprises cyclodextrin, polymer, therapeutic drug, silicon nanoparticles and a cross-linker.
2. The polymer conjugate as claimed in claim 1, wherein the polymer conjugate optionally comprises a target lig and.
3. The polymer conjugate as claimed in claim 1, wherein cyclodextrin is preferably ?-cyclodextrin.
4. The polymer conjugate as claimed in claim 1, wherein the polymer is a water soluble polymer, polyvinyl-pyrrolidone (PVP).
5. The polymer conjugate as claimed in claim 1, wherein therapeutic agent may be selected from Doxycycline, ciprofloxacin, bupivacaine or 2-hydroxypropyl-ß-cyclodextrin.
6. The polymer conjugate as claimed in claim 1, wherein therapeutic agent can be added to the CD-PVP complex through a linker.
7. The polymer conjugate as claimed in claim 6, wherein the linker is selected from PEG polymer, Folic acid, mono- and oligosaccharides, hyaluronic acid (HA) or an antibody.
8. The polymer conjugate as claimed in claim 1, wherein target ligand is selected from Doxycycline, ciprofloxacin, bupi vacaine and 2-hydroxypropyl-ß-cyclodextrin.
9. The polymer conjugate as claimed in claim 1, wherein target lig and may be mounted on the monomer via an optional linker or grafted on to the polymer via an optional linker, or the combination can be bound as an inclusion complex or host-guest.
10. The polymer conjugate as claimed in claim 1, wherein the polymer conjugate is water-soluble and linear.
11. The polymer conjugate as claimed in claim 1, wherein the polymer conjugate displays high solubility in water, low toxicity and low immune response.
12. The polymer conjugate as claimed in claim 1, wherein the polymer conjugate is capable of targeted delivery of therapeutic agents at a controlled rate in penetrating biofilms especially for dental carries.
13. The polymer conjugate as claimed in claim 1, wherein the polymer conjugate does not alter the therapeutic efficacy of the therapeutic agent used.
14. The polymer conjugate as claimed in claim 1, wherein is encapsulated with appropriate lipophilic nanoparticles, preferably allyl-benzyl-capped silicon nanoparticles.
15. The polymer conjugate as claimed in claim 14, wherein the nanoparticles of lipophilic allyl-benzyl-capped silicone in a single fraction have size in the range of 1 nm and 5 nm.
16. The polymer conjugate as claimed in claim 15, wherein a particular size of the nanoparticles of lipophilic allyl-benzyl-capped silicone is separated using selective precipitation.
17. The polymer conjugate as claimed in claims 14-16, wherein the polymer conjugate is bound to lipophilic allyl-benzyl-capped silicon nanoparticles with a homodifunctionalized cross-linker, glutaraldehyde for easy enzymatic digestion and for releasing drug targets.
18. The polymer conjugate as claimed in claims 14-17, wherein functional group of lipophilic allyl-benzyl-capped silicon nanoparticles opens to accommodate drug targets at the site.
19. The polymer conjugate as claimed in claim 1, wherein cyclodextrin moiety and PVP co-monomer are arranged with alternating water-soluble linear polymers of CD-PVP that are covalently bound to therapeutic agent.
20. The polymer conjugate as claimed in claim 1, wherein co-polymerizing of CD and PVP leads to conjugates having reactive site to covalently bind PVP and opening another site for binding therapeutic agent or for forming CD-PVP alternating cassette intercalating the therapeutic agent.
21. A method of making the polymer conjugate of cyclodextrin with polyvinyl-pyrrolidine, as claimed in claim 1, the method comprising the steps of :
a) adding?- cyclodextrin topolyvinyl-pyrrolidine in the amount of 20%w/v;
b) Incubating the mixture of step a) at 90 degrees C for 1 hour, using a waterbath;
c) addition of sodium hydroxide after 5-10 min of incubation;
d) incubating the mixture of step c) at 90 degrees C for 6 hours; and
e) taking readings at 450 nm to characterize and confirm the product.